866-997-4948(US-Canada Toll Free)

Nonmelanomatous Skin Cancer Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Cancer

No. of Pages : 36 Pages


Nonmelanomatous Skin Cancer Pipeline Review, H2 2012

Global Markets Directs, 'Nonmelanomatous Skin Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Nonmelanomatous Skin Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nonmelanomatous Skin Cancer. Nonmelanomatous Skin Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Nonmelanomatous Skin Cancer.
  • A review of the Nonmelanomatous Skin Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Nonmelanomatous Skin Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Nonmelanomatous Skin Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Nonmelanomatous Skin Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Nonmelanomatous Skin Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Nonmelanomatous Skin Cancer 7
Nonmelanomatous Skin Cancer Therapeutics under Development by Companies 9
Nonmelanomatous Skin Cancer Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Nonmelanomatous Skin Cancer Therapeutics Products under Development by Companies 14
Nonmelanomatous Skin Cancer Therapeutics Products under Investigation by Universities/Institutes 15
Companies Involved in Nonmelanomatous Skin Cancer Therapeutics Development 16
Almirall, S.A. 16
PharmaQest Pty. Ltd. 17
Nonmelanomatous Skin Cancer Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
Isotretinoin + Interferon Alpha 2a - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
aminolevulinic acid hydrochloride - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
imiquimod - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Eflornithine + Triamcinolone - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
diclofenac sodium - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
LAS-41007 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
tarenflurbil - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Nonmelanomatous Skin Cancer Therapeutics Drug Profile Updates 31
Nonmelanomatous Skin Cancer Therapeutics - Dormant Products 32
Nonmelanomatous Skin Cancer Product Development Milestones 33
Featured News & Press Releases 33
Aug 27, 2004: Initiation Of Human Trials 33
Jun 29, 2004: INDs For Peplins Lead Product Filed With FDA 33
Nov 25, 2002: Allergan In-Licenses A Compound For The Treatment Of Non-Melanoma Skin Cancers From Peplin Biotech 34

Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36

List of Table


Number of Products Under Development for Nonmelanomatous Skin Cancer, H2 2012 7
Products under Development for Nonmelanomatous Skin Cancer Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Almirall, S.A., H2 2012 16
PharmaQest Pty. Ltd., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Nonmelanomatous Skin Cancer Therapeutics Drug Profile Updates 31
Nonmelanomatous Skin Cancer Therapeutics Dormant Products 32

List of Chart


Number of Products under Development for Nonmelanomatous Skin Cancer, H2 2012 7
Products under Development for Nonmelanomatous Skin Cancer Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *